FDG PET-CT

RADIATION4 trials

Sponsors

Jules Bordet Institute, University Hospital, Toulouse, Institute of Cancer Research, United Kingdom, Centre Hospitalier Universitaire de Nice

Conditions

CancerColorectal CancerFertilityMetastatic Melanoma

Unknown Phase

Correlating the Tumoral Metabolic Progression Index to Patient's Outcome in Advanced Colorectal Cancer

CompletedNCT01591590

Jules Bordet InstituteColorectal Cancer

Start: 2012-06-30End: 2021-09-25Updated: 2021-10-26

Secretory Azoospermia and FDG (Fluoro Deoxyglucose) PET-CT

CompletedNCT02043444

University Hospital, ToulouseFertility

Start: 2014-01-31End: 2019-12-31Updated: 2026-01-06

Imaging NSCLC Treatment Response to Immunotherapy

CompletedNCT02753569

Institute of Cancer Research, United KingdomCancer

Start: 2016-05-31End: 2020-05-14Updated: 2021-02-01

Interim FDG PET-CT in Melanoma Metastatic Patient's Treated by Anti-PD1 Therapy

RecruitingNCT03888950

Centre Hospitalier Universitaire de NiceMetastatic Melanoma

Start: 2020-11-24End: 2027-11-30Target: 20Updated: 2025-03-19

Related Papers

18F-FDG PET scan and liquid biopsy as tools to assess the pace of tumor progression and to predict overall survival (OS) in refractory colorectal cancer (rCRC): The CORIOLAN trial.

Journal of Clinical Oncology2020-05-20

Correlating tumor metabolic progression index measured by serial FDG PET-CT, apparent diffusion coefficient measured by magnetic resonance imaging (MRI) and blood genomics to patient's outcome in advanced colorectal cancer: the CORIOLAN study.

2014-05-302 citations